J&J Options In Face Of Merck’s Schering Bid Include OTC Deal
This article was originally published in The Tan Sheet
Executive Summary
One option for Johnson & Johnson in response to Merck's bid for Schering-Plough is to make a deal for the latter's consumer health business
You may also be interested in...
Merck Gives Consumer Health Care Division Direct Line To CEO
Merck is searching for an executive to lead its new consumer health care division to international growth once its $41.1 billion merger with Schering-Plough closes
Merck Gives Consumer Health Care Division Direct Line To CEO
Merck is searching for an executive to lead its new consumer health care division to international growth once its $41.1 billion merger with Schering-Plough closes
Merck Gives Consumer Health Care Division Direct Line To CEO
Merck is searching for an executive to lead its new consumer health care division to international growth once its $41.1 billion merger with Schering-Plough closes